Pfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call Transcript

So that’s why we are not commenting much of that. And we will, let’s say, continue being very active in the obesity space and one we’re in now. Now what about the mRNA flu vaccine and anything you want to add also to the obesity line?

Mikael Dolsten: I think you said it so well on obesity. I’ll focus on mRNA vaccine and just say that we did share that we had a very robust payable data for 18 to 59 in the outcome event trial on the first-generation flu mRNA platform. We actually further refined that product in order to expand activity against these serotypes although the disease is dominated by A, we saw an opportunity to do that. And that technology is now with the COVID/flu combo vaccine running for 18 to 59 years old and relatively soon, we’ll have a readout. We think that’s really the near-term opportunity to bring both of the viruses under one simple administration approach. For the 65-plus, what you referred to was an early trial with the first generation. We have now moved focus to the second generation and are in preparation of subsequent clinical studies on that.

Albert Bourla: Thank you, Mikael. So thank you, operator, and thank you, everyone for your interest. That was a very good call. In summary, we are very pleased with the solid start in 2024. We are cautiously optimistic about the year ahead. And with our continued progress in executing our five priorities, we are confident that we will continue to deliver for our patients, shareholders, and our company. Thank you again for your interest in Pfizer. We hope you have a wonderful day. Thank you.

Operator: Thank you. This does conclude today’s program. Thank you for your participation. You may disconnect at any time and have a wonderful day.